In drug discovery research utilizing AI and machine learning, the biggest factor influencing the accuracy of predictive models is "data quality." Excelra and Patcore will co-host a free online webinar on the theme of GOSTAR(TM), which accelerates AI drug discovery, on June 11, 2026, at 13:30. Utilizing GOSTAR(TM), one of the world's largest manually curated SAR databases, the webinar will explain, with live demonstrations, the acceleration of predictive modeling using ML-ready data, improvements in molecular design accuracy in medicinal chemistry, and the establishment of a data foundation that supports go/no-go decisions from lead optimization. The speaker will be Dr. Nishanth Kandepedu from Excelra, who has over 10 years of experience in the drug discovery field. Researchers in drug discovery from pharmaceutical and biotech companies, AI/ML engineers, and R&D leaders are widely invited to participate. Participation is free, but prior registration is required. Registration will close once capacity is reached. ▼Details & Registration: https://patcore.com/news/webinar-gostar-2026

As incidents related to dangerous drugs continue to emerge as a social issue, the Ministry of Health, Labour and Welfare has introduced "comprehensive designation," which categorizes substances with similar structural components as illegal drugs. This includes strengthening regulations on the manufacture and sale of designated drugs, as well as prohibiting possession and use. Additionally, Tokyo, which has its own drug regulations, is also strengthening penalties under the "Tokyo Ordinance on the Prevention of Drug Abuse." For pharmaceutical and chemical companies that handle various chemical substances daily, it has become essential to verify the latest legal regulations concerning the chemicals they intend to handle before taking any action. However, the increasing regulatory burden raises the risk of overlooking regulatory information. The CRAIS Checker, which rapidly determines the regulatory status of chemical substances based on their structural formulas, addresses recent regulations that are difficult to manage through investigations of CAS numbers or lists of regulated substances, thereby supporting quicker and more reliable compliance responses. Furthermore, our regulatory substance check technology has been selected as a solution for regulatory drug compliance by the non-profit organization Pistoia Alliance, and we also offer a "Compliance Checker" that complies with drug regulations in North America, various European countries, and India, which is available in the global market.

Patcora Inc. (CEO: Akihiro Nakamura, Headquarters: Chiyoda, Tokyo) will launch "QuickPat," a patent specification drafting support system commercialized based on a patent specification experimental item creation support system developed by a major domestic pharmaceutical company. This system enables the reduction of the diverse work time required for creating patent specification experimental items to less than about one-third (※), contributing to the acceleration of new drug research and development. The system utilizes internal information assets such as electronic notebooks and compound/active databases to create drafts of experimental items, significantly shortening the time required for drafting patent specification experimental items. Additionally, various checking mechanisms allow for the creation of accurate and robust experimental items. Along with the sale of this system, integration services will be provided to connect the electronic lab notebooks of implementing companies and reflect their patent specification drafting policies. Patcora is focused on the chemical information systems business and aims to contribute to the acceleration of new drug research and development through highly specialized solutions. (※) Based on the experiences of existing users from surveys; results may vary by case.